Ubs Group Ag Xtl Biopharmaceuticals LTD Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Xtl Biopharmaceuticals LTD stock. As of the latest transaction made, Ubs Group Ag holds 1,336 shares of XTLB stock, worth $1,563. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,336

Holding current value

$1,563

% of portfolio

0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$0.95 - $1.53 $1,269 - $2,044	1,336 New	1,336 $1,000
Q1 2024 May 13, 2024	BUY	$0.8 - $3.07 $5,520 - $21,183	6,900 Added 12777.78%	6,954 $19,000
Q4 2023 Feb 09, 2024	SELL	$0.76 - $1.13 $50 - $74	-66 Reduced 55.0%	54 $0
Q3 2023 Nov 09, 2023	BUY	$0.77 - $1.05 $92 - $126	120 New	120 $0
Q4 2022 Feb 08, 2023	BUY	$1.04 - $1.48 $312 - $444	300 New	300 $0
Q2 2022 Aug 10, 2022	SELL	$1.38 - $2.4 $1,120 - $1,948	-812 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.13 - $2.91 $1,401 - $1,914	658 Added 427.27%	812 $2,000
Q4 2021 Feb 14, 2022	SELL	$2.63 - $4.41 $7,216 - $12,101	-2,744 Reduced 94.69%	154 $0
Q3 2021 Nov 15, 2021	BUY	$3.43 - $5.2 $9,940 - $15,069	2,898 New	2,898 $13,000
Q2 2021 Aug 13, 2021	SELL	$3.0 - $3.99 $10,572 - $14,060	-3,524 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$2.89 - $4.15 $10,184 - $14,624	3,524 New	3,524 $12,000
Q4 2020 Feb 11, 2021	SELL	$1.83 - $3.17 $1,895 - $3,284	-1,036 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$1.37 - $2.21 $1,419 - $2,289	1,036 New	1,036 $2,000
Q1 2020 May 01, 2020	SELL	$0.9 - $1.64 $1,101 - $2,007	-1,224 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$1.2 - $1.67 $2,524 - $3,513	-2,104 Reduced 63.22%	1,224 $2,000
Q3 2019 Nov 14, 2019	SELL	$1.44 - $2.1 $288 - $420	-200 Reduced 5.67%	3,328 $5,000
Q2 2019 Aug 14, 2019	SELL	$1.95 - $2.5 $5,460 - $7,000	-2,800 Reduced 44.25%	3,528 $7,000
Q1 2019 May 14, 2019	SELL	$1.72 - $2.61 $589 - $895	-343 Reduced 5.14%	6,328 $15,000
Q4 2018 Feb 14, 2019	BUY	$1.43 - $2.98 $308 - $643	216 Added 3.35%	6,671 $12,000
Q3 2018 Nov 14, 2018	BUY	$1.7 - $2.21 $9,797 - $12,736	5,763 Added 832.8%	6,455 $14,000
Q2 2018 Aug 14, 2018	SELL	$1.55 - $2.41 $677 - $1,053	-437 Reduced 38.71%	692 $1,000
Q1 2018 May 15, 2018	BUY	$1.64 - $2.55 $698 - $1,086	426 Added 60.6%	1,129 $2,000
Q4 2017 Feb 14, 2018	SELL	$2.16 - $2.69 $5,047 - $6,286	-2,337 Reduced 76.88%	703 $2,000
Q3 2017 Nov 14, 2017	SELL	$2.4 - $2.84 $31,845 - $37,683	-13,269 Reduced 81.36%	3,040 $7,000
Q2 2017 Aug 14, 2017	BUY	N/A	10,989 Added 206.56%	16,309 $52,000
Q1 2017 Nov 14, 2017	BUY	N/A	5,320	5,320 $14,000

Others Institutions Holding XTLB

# of Institutions

Shares Held

427K

Call Options Held

Put Options Held

View Full List

About XTL BIOPHARMACEUTICALS LTD

Ticker XTLB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,449,060
Market Cap $6.38M
Description
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Ye...

More about XTLB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account